Cargando…
Comprehensive clinical evaluation of moxifloxacin: A retrospective study
The objective was to provide a basis for the rational clinical application of moxifloxacin through its comprehensive clinical evaluation, and to serve as a reference for the clinical comprehensive evaluation of relevant drugs in the future. We obtained data from 91 community-acquired pneumonia patie...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10238022/ https://www.ncbi.nlm.nih.gov/pubmed/37266643 http://dx.doi.org/10.1097/MD.0000000000033896 |
_version_ | 1785053203587399680 |
---|---|
author | Wang, Hailiang Liu, Haiqiang Lou, Meimei Xu, Lanxia Zhang, Wei Jing, Lijun Fu, Min Liu, Bing |
author_facet | Wang, Hailiang Liu, Haiqiang Lou, Meimei Xu, Lanxia Zhang, Wei Jing, Lijun Fu, Min Liu, Bing |
author_sort | Wang, Hailiang |
collection | PubMed |
description | The objective was to provide a basis for the rational clinical application of moxifloxacin through its comprehensive clinical evaluation, and to serve as a reference for the clinical comprehensive evaluation of relevant drugs in the future. We obtained data from 91 community-acquired pneumonia patients admitted to Weifang people’s hospital from April 2020 to November 2021, including 46 in the evaluation group and 45 in the control group. Based on the requirements of the “Guidelines for the Management of Comprehensive Clinical Evaluation of Drugs” (for trial implementation), systematic evaluations are conducted in terms of drug safety, effectiveness, economy, innovation, suitability, and accessibility. The incidence of adverse drug reactions was low, drug quality, safety and stable efficacy; treatment efficiency was 91.3% and 93.3%, respectively (P > .05); the average total cost of the evaluation group was 9765.28RMB and 10250.69RMB, respectively; efficient cost-effectiveness ratio was 104.67 and 112.52 and cost-effectiveness ratio was 242.71. The economy of the evaluation group had a low price and was highly available. |
format | Online Article Text |
id | pubmed-10238022 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Lippincott Williams & Wilkins |
record_format | MEDLINE/PubMed |
spelling | pubmed-102380222023-06-03 Comprehensive clinical evaluation of moxifloxacin: A retrospective study Wang, Hailiang Liu, Haiqiang Lou, Meimei Xu, Lanxia Zhang, Wei Jing, Lijun Fu, Min Liu, Bing Medicine (Baltimore) 4900 The objective was to provide a basis for the rational clinical application of moxifloxacin through its comprehensive clinical evaluation, and to serve as a reference for the clinical comprehensive evaluation of relevant drugs in the future. We obtained data from 91 community-acquired pneumonia patients admitted to Weifang people’s hospital from April 2020 to November 2021, including 46 in the evaluation group and 45 in the control group. Based on the requirements of the “Guidelines for the Management of Comprehensive Clinical Evaluation of Drugs” (for trial implementation), systematic evaluations are conducted in terms of drug safety, effectiveness, economy, innovation, suitability, and accessibility. The incidence of adverse drug reactions was low, drug quality, safety and stable efficacy; treatment efficiency was 91.3% and 93.3%, respectively (P > .05); the average total cost of the evaluation group was 9765.28RMB and 10250.69RMB, respectively; efficient cost-effectiveness ratio was 104.67 and 112.52 and cost-effectiveness ratio was 242.71. The economy of the evaluation group had a low price and was highly available. Lippincott Williams & Wilkins 2023-06-02 /pmc/articles/PMC10238022/ /pubmed/37266643 http://dx.doi.org/10.1097/MD.0000000000033896 Text en Copyright © 2023 the Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial License 4.0 (CCBY-NC) (https://creativecommons.org/licenses/by-nc/4.0/) , where it is permissible to download, share, remix, transform, and buildup the work provided it is properly cited. The work cannot be used commercially without permission from the journal. |
spellingShingle | 4900 Wang, Hailiang Liu, Haiqiang Lou, Meimei Xu, Lanxia Zhang, Wei Jing, Lijun Fu, Min Liu, Bing Comprehensive clinical evaluation of moxifloxacin: A retrospective study |
title | Comprehensive clinical evaluation of moxifloxacin: A retrospective study |
title_full | Comprehensive clinical evaluation of moxifloxacin: A retrospective study |
title_fullStr | Comprehensive clinical evaluation of moxifloxacin: A retrospective study |
title_full_unstemmed | Comprehensive clinical evaluation of moxifloxacin: A retrospective study |
title_short | Comprehensive clinical evaluation of moxifloxacin: A retrospective study |
title_sort | comprehensive clinical evaluation of moxifloxacin: a retrospective study |
topic | 4900 |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10238022/ https://www.ncbi.nlm.nih.gov/pubmed/37266643 http://dx.doi.org/10.1097/MD.0000000000033896 |
work_keys_str_mv | AT wanghailiang comprehensiveclinicalevaluationofmoxifloxacinaretrospectivestudy AT liuhaiqiang comprehensiveclinicalevaluationofmoxifloxacinaretrospectivestudy AT loumeimei comprehensiveclinicalevaluationofmoxifloxacinaretrospectivestudy AT xulanxia comprehensiveclinicalevaluationofmoxifloxacinaretrospectivestudy AT zhangwei comprehensiveclinicalevaluationofmoxifloxacinaretrospectivestudy AT jinglijun comprehensiveclinicalevaluationofmoxifloxacinaretrospectivestudy AT fumin comprehensiveclinicalevaluationofmoxifloxacinaretrospectivestudy AT liubing comprehensiveclinicalevaluationofmoxifloxacinaretrospectivestudy |